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BRIEF CLINICAL REPORTSVasopressin withdrawal associated with massive polyuria
Candy S. Peskey, PharmD,a William J. Mauermann, MD,b Steven R. Meyer, MD, PhD,c and
Martin D. Abel, MD,d Rochester, MinnVasopressin has demonstrated success in the treatment of
vasodilatory shock.1 It is also frequently used to manage de-
creased systemic vascular resistance (SVR) during or after
cardiac surgery with cardiopulmonary bypass. We report
a case of massive polyuria and increasing serum tonicity
after withdrawal of a vasopressin infusion in a patient after
cardiac surgery.
CLINICAL SUMMARY
A 32-year-old man with Marfan’s syndrome treated with
atenolol and lisinopril underwent repair of an ascending aor-
tic aneurysm, closure of a patent foramen ovale, and mitral
valve repair. After termination of cardiopulmonary bypass,
a vasopressin infusion (0.08 U/min) was initiated for persis-
tent hypotension caused by decreased SVR (456 dynes $
sec1 $ cm5). The vasopressin infusion was continued for
3 days, at which time the infusion was withdrawn over 12
hours. During this period, the patient was awake and alert
and had free access to oral fluids.
Within 3 hours of discontinuing the vasopressin infusion,
the patient’s urine output increased to more than 1 L/h with-
out any other medication changes, and oral fluid intake aver-
aged 300 mL/h (Figure 1). Specifically, no diuretics had
been administered for at least 24 hours. The serum sodium
concentration (normal range, 135–145 mmol/L) increased
to 135 mmol/L from 129 mmol/L. During the diuresis, urine
osmolality measured 164 mOsm (normal, 300–800 mOsm/
kg), and serum osmolality was 272 mOsm (normal, 275–
295 mOsm/kg). The excretion of large volumes of dilute
urine with an increasing systemic tonicity is consistent
with diabetes insipidus, and we presumed this to be the diag-
nosis.1 On administration of 25 mg of desmopressin intrave-
nously, the urine output decreased to an average of 66 mL/h
over 6 hours, and urine osmolality increased to 623 mOsm/
kg, suggesting a diagnosis of central diabetes insipidus.
A subsequent dose of desmopressin was required 24 hours
later for increased urine output.
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Arginine vasopressin, or antidiuretic hormone, is a nona-
peptide hormone produced in the hypothalamus and stored
in and released from the posterior pituitary gland.1 Vaso-
pressin release occurs primarily in response to increased se-
rum osmolality, as well as hypotension and hypovolemia.
Vasopressin activates V1 receptors in blood vessels, causing
vasoconstriction; V2 receptors in the collecting tubules of
the kidney, promoting water reabsorption; and V3 receptors
in the central nervous system, regulating corticotropin-re-
leasing hormone and possibly other neurotransmitters.1
Although vasopressin is used in the setting of decreased
SVR for its vasoconstrictive properties, the increase in
plasma volume caused by free water reabsorption augments
its effect on blood pressure.2 Adverse effects associated with
the use of vasopressin in hypotension are caused by either
this vasoconstriction or an increase in free water. Most of
these effects are mild and include blanching of the skin, ab-
dominal cramping, and nausea. Rare complications include
water intoxication, acute coronary syndrome, and ischemic
colitis.
Vasoplegia after cardiac surgery is increasingly being rec-
ognized and might be related to the use of angiotensin recep-
tor blockers or angiotensin-converting enzyme inhibitors,
which this patient was taking preoperatively.3 In this report
we describe a case of massive polyuria that occurred in
association with the withdrawal of vasopressin to treat vaso-
plegia after cardiac surgery. There are 3 possible explana-
tions: primary polydipsia, iatrogenic hyponatremia, or
transient central diabetes insipidus.
Primary polydipsia is defined as the compulsive ingestion
of water, resulting in hyposmolality. In the face of fluid dep-
rivation, these patients are able to concentrate their urine and
normalize their serum osmolality. We cannot exclude this
explanation for the patient’s clinical condition because
a fluid deprivation test was not performed. However, an in-
creasing serum sodium level makes this unlikely.
Iatrogenic hyponatremia caused by the use of a vasopres-
sin infusion might have caused a syndrome similar to that
seen with inappropriate antidiuretic hormone secretion.
The discontinuation of vasopressin in this patient might
have led to compensatory diuresis with the production of
a large volume of dilute urine that in turn resulted in an in-
crease in serum sodium and osmolality. However, this ex-
planation does not account for the polydipsia seen in this
patient after discontinuation of vasopressin. Vasopressin in-
fusions are commonly used to treat vasoplegia after cardiac
surgery. To our knowledge, iatrogenic hyponatremia caused
by the use of vasopressin in this setting has not been
reported.ardiovascular Surgery c Volume 138, Number 2 491
Brief Clinical ReportsFIGURE 1. Temporal relationship of vasopressin infusion (dashed line, left ordinate), urine output (solid line, right ordinate), and serum sodium concen-
tration (diamonds; in millimoles per liter). DDAVP, (desmopressin).A third possible explanation for this patient’s clinical pre-
sentation is a form of transient central diabetes insipidus.
Central diabetes insipidus is caused by a deficiency of en-
dogenous vasopressin that results in polyuria and hyperos-
molality. In the awake patient the resultant polydipsia
maintains normal serum osmolality in the face of the produc-
tion of large volumes of dilute urine. Fluid deprivation in
such a patient would result in hyperosmolality and hyperna-
tremia. In the patient described in this report, we speculate
that the withdrawal of vasopressin resulted in a transient
form of central diabetes insipidus, causing polyuria and an
increasing serum sodium level. Treatment with desmopres-
sin proved effective in normalizing urine output and prevent-
ing hypernatremia. We cannot be certain of this diagnosis
because a fluid deprivation test was not performed and the
patient had ready access to an unlimited supply of fluids.
The occurrence of transient diabetes insipidus resulting
from the withdrawal of vasopressin infusions theoretically
might be due to negative-feedback inhibition of endogenous
vasopressin production and release occurring through the
V3 receptor. Alternatively, endogenously synthesized vaso-
pressin in this patient might have been depleted because of492 The Journal of Thoracic and Cardiovascular Suincreased demand from the hypovolemic state, and with-
drawal of exogenously administered vasopressin simply un-
masked this deficit.4
Regardless of the diagnosis or mechanism, polyuria and
changes in serum tonicity after withdrawal of exogenously
administered vasopressin appear to resolve spontaneously
over time. In the case described here, only a short course
of vasopressin agonist therapy was required to temporarily
maintain free water balance. Overall, there are few reported
adverse effects of vasopressin, despite increasing therapeu-
tic use. The occurrence of polyuria and increasing serum so-
dium after continuous vasopressin administration represents
an uncommon but serious possibility and warrants ongoing
surveillance.
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